Aardvark Therapeutics Cash Flow Statement (2024-2026) | AARD

Cash Flow Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter) -2.07M-5.48M-4.09M-11.91M-9.30M-14.38M-16.35M-17.58M-21.57M
Share-based Compensation (Quarter) 0.07M0.05M0.14M0.17M0.23M0.63M1.50M1.58M25.90M
Asset Writedowns and Impairment (Quarter) 0.10M0.01M
Cash from Operations (Quarter) -2.19M-4.21M-3.96M-7.73M-11.39M-9.84M-16.13M-16.81M-18.87M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter) 0.10M0.08M0.62M0.37M0.23M0.12M
Depreciation & Amortization (CF) (Quarter) 0.00M-0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Change in Working Capital
Change in Account Payables (Quarter) -0.45M0.63M-0.58M1.19M0.65M2.58M-0.61M-2.37M2.42M
Change in Accured Expenses (Quarter) 0.48M0.61M0.29M-0.00M1.41M1.81M1.03M2.17M-1.26M
Other Working Capital Changes (Quarter) -0.03M-0.03M-0.06M-0.09M-0.05M-0.08M-0.10M-0.10M-0.10M
Investing Activities
Capital Expenditures (Quarter) 0.01M0.09M0.01M0.01M0.09M0.00M
Change in Acquisitions & Divestments (Quarter) 12.03M9.50M29.25M29.25M34.25M
Cash from Investing Activities (Quarter) -0.01M-0.09M-0.01M-11.89M-112.62M9.41M29.25M24.30M34.25M
Financing Activities
Other financing activities (Quarter) 0.17M1.02M0.11M90.97M-91.08M
Change in Capital Stock
Shares Issued (Quarter) 0.99M3.04M
Net Equity Issued and Repurchased (Quarter) -85.00M0.20M
Misc.
Cash from Financing Activities (Quarter) 82.94M0.06M-1.01M88.88M-0.07M0.17M0.27M0.00M
Change in Cash (Quarter) -2.19M78.63M-3.90M-20.64M-35.14M-0.51M13.29M7.77M15.38M
Free Cash Flow (Quarter) -2.19M-4.31M-3.96M-7.73M-11.39M-9.94M-16.13M-16.81M-18.87M
Net Cash Flow (Quarter) -2.19M78.63M-3.90M-20.64M-35.14M-0.51M13.29M7.77M15.38M